![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-13-2023-38736.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-25-2023-66768.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-dextromethorphan-hydrobromide-and-bupropion-hydrochloride-extended-release-tablet-83509.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-22-2023-51785.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216766
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208043
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-18-2022-1653024384.pdf
https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-publication-pivotal-ascend-phase-2
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215568
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210015
https://www.prnewswire.com/news-releases/currax-pharmaceuticals-announces-the-appointment-of-ed-cinca-to-senior-vice-president-global-marketing-and-strategic-alliance-management-301408090.html
https://www.pharmacompass.com/pdf/news/health-canada-issues-recall-of-sun-pharmas-taro-bupropion-xl-1632832436.pdf
https://www.prnewswire.com/news-releases/nida-funded-study-evaluating-extended-release-injectable-naltrexone-plus-bupropion-for-the-treatment-of-methamphetamine-use-disorder-published-in-new-england-journal-of-medicine-301208061.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208606
https://www.patentdocs.org/2019/08/nalproprion-pharmaceuticals-inc-v-actavis-laboratories-fl-inc-fed-cir-2019.html
https://www.gov.uk/drug-safety-update/naltrexone-bupropion-mysimba-risk-of-adverse-reactions-that-could-affect-ability-to-drive
https://www.biospace.com/article/how-the-pharmaceutical-industry-is-looking-to-treat-low-sex-drive/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211020
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-14-2018-1542217134.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210497
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211347
https://www.accessdata.fda.gov/scripts/ires/index.cfm?action=print.getPrintData&ts=8262018111931
https://www.forbes.com/sites/joshuacohen/2018/09/10/belviq-study-results-may-improve-the-fortunes-of-weight-loss-drugs/#2cefd3836a40
https://www.pharmacompass.com/pdf/news/Enforcement-Report-Week-of-August-22-2018-1534903909.pdf
https://www.fiercepharma.com/marketing/eisai-obesity-drug-belviq-picks-up-edge-long-awaited-heart-safety-data
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203013
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-11-2018-1523421880.pdf
https://endpts.com/with-debt-looming-browbeaten-diet-pill-maker-orexigen-goes-bankrupt/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-31-2018-1517375593.pdf
http://www.pharmatimes.com/news/final_nhs_no_for_obesity_pill_mysimba_1214102
https://www.prnewswire.com/news-releases/orexigen-therapeutics-announces-commercialization-and-distributorship-agreement-with-merck-kgaa-darmstadt-germany-for-contrave-in-latin-america-300554337.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210081
https://www.pharmacompass.com/pdf/news/ema-recommends-suspension-of-medicines-due-to-unreliable-studies-from-micro-therapeutic-research-labs-1503552764.pdf
https://www.pharmacompass.com/pdf/news/international-laboratories-llc-issues-voluntary-nationwide-recall-of-one-1-lot-of-pravastatin-sodium-tablets-usp-40mg-packaged-in-bottles-of-30-tablets-1502427855.pdf
http://www.pharmatimes.com/news/nice_bars_obesity_pill_from_routine_nhs_use_1199805
http://www.prnewswire.com/news-releases/orexigen-therapeutics-announces-expansion-of-distributorship-agreement-with-biologix-fzco-for-contrave-naltrexone-hcl--bupropion-hcl-extended-release-to-egypt-300494141.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-5-2017-1499230453.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207224
http://www.pharmatimes.com/news/nice_rejects_orexigens_weight-loss_pill_1192361
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-19-2017-1492575710.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207479
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090693
http://www.indiainfoline.com/article/news-top-story/lupin-receives-fda-approval-lupin-receives-fda-approval-for-generic-wellbutrin-xl-tablets-117041000026_1.html
http://www.moneycontrol.com/news/business/sun-pharma-recalls-27-lakh-bottlesantidepressantus_8430161.html
http://www.prnewswire.com/news-releases/orexigen-therapeutics-announces-spanish-launch-of-mysimba-naltrexone-hcl--bupropion-hcl-prolonged-release-in-partnership-with-laboratorios-farmaceuticos-rovi-sa-300396318.html